“I mentioned the COVID-related vaccine and therapeutic bioprocessing business. They'll probably be roughly flat here in 2022.”

In context

“nvestors. So I just wanted to circle back on it. I mean it sounds like you feel really good about that underlying base business growing in the low double digits. And then the vaccine piece, maybe a little bit more of a variable. But can you just talk, I guess, about the trajectory? It sounded like '22 is a decent proxy where maybe COVID comes down, and you shake out somewhere in the mid-high single digits as a whole for that kind of $7.5 billion business. I was just hoping you could talk a little bit about the puts and takes as we go through kind of the next few years. And again, that vaccine piece comes down, but the base business seems like it's good enough to offset that and then some, but just wanted to get a better handle there. Rainer Blair: I think that's right. As we look at 2022, I mentioned the COVID-related vaccine and therapeutic bioprocessing business. They'll probably be roughly flat here in 2022. Again, the assumption being that we're starting to see the pandemic going endemic on the one hand. On the other hand, what you start seeing -- you start seeing to happen is, if you will, we're going from 1.0 compounds to 2.0. So some vaccines and therapeutics are viewed as less efficacious in the current environment with the current variance, and so those become less of a factor. On the other hand, you have new monoclonal antibodies as therapeutics starting to be proposed that show much higher efficacy here with the variance that you have. And then for those that are already in market and quite effective, we're starting to see the recurring revenue as those companies are starting to recognize the recurring need for booster shots, not just here but around the globe. So we think that that's”